BioAge CMO sells 8,820 shares after exercising
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin exercised stock options and then sold the resulting shares.
Rhea-AI Filing Summary
BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin exercised stock options and then sold the resulting shares. On April 1, 2026, he exercised options covering 8,820 shares of common stock at strike prices of $4.11 and $6.57 per share.
The same day, he sold 8,820 shares of common stock at $17.81 per share in an open-market transaction, leaving 0 shares of common stock held directly after the sale. The filing notes that the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 8,820 shares ($113K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
RUBIN PAUL D
Role
Chief Medical Officer
Sold
8,820 shs ($157K)
Approx. gross sale proceeds
$157K
Approx. exercise cost
$45K
Approx. pre-tax spread
$113K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 5,437 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 3,383 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,437 | $4.11 | $22K |
| Exercise | Common Stock | 3,383 | $6.57 | $22K |
| Sale | Common Stock | 8,820 | $17.81 | $157K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.
- F2. This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.
- F3. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Key Figures
Shares sold: 8,820 shares
Sale price: $17.81 per share
Options exercised (tranche 1): 5,437 shares at $4.11
+4 more
7 metrics
Shares sold
8,820 shares
Common stock sold on April 1, 2026
Sale price
$17.81 per share
Open-market sale of common stock
Options exercised (tranche 1)
5,437 shares at $4.11
Stock Option (Right to Buy), exercise or conversion
Options exercised (tranche 2)
3,383 shares at $6.57
Stock Option (Right to Buy), exercise or conversion
Total options exercised
8,820 shares
ExerciseShares in transactionSummary
Shares held after sale
0 shares
Total shares of common stock following transaction
10b5-1 plan adoption date
November 5, 2024
Rule 10b5-1 trading plan footnote
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy, derivative exercise/conversion, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy financial
""security_title": "Stock Option (Right to Buy)","
derivative exercise/conversion financial
""transaction_action": "derivative exercise/conversion","
open-market sale financial
""transaction_action": "open-market sale","
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Exercise or conversion of derivative security financial
""transaction_code_description": "Exercise or conversion of derivative security","
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BIOA’s Chief Medical Officer report on this Form 4?
BioAge Labs’ Chief Medical Officer Paul D. Rubin reported exercising stock options for 8,820 common shares and then selling all 8,820 shares. The transactions occurred on April 1, 2026 and are detailed as option exercises followed by an open-market sale.
What stock options did BIOA’s CMO exercise in this Form 4 filing?
He exercised two tranches of stock options: 5,437 options with a $4.11 exercise price and 3,383 options with a $6.57 exercise price. Together, these options converted into 8,820 shares of BioAge Labs common stock on April 1, 2026.
Was the BIOA insider sale by the CMO made under a Rule 10b5-1 plan?
Yes. The Form 4 states the transaction was executed under a Rule 10b5-1 trading plan adopted by Paul D. Rubin on November 5, 2024. Such plans pre-schedule trades, making the timing more routine and less discretionary.
What are the CMO’s direct BioAge Labs (BIOA) common stock holdings after this Form 4?
After the reported transactions, Paul D. Rubin directly holds 0 shares of BioAge Labs common stock. The Form 4 lists 8,820 shares sold and shows total shares of common stock following the sale as zero in his direct ownership.
AI-generated analysis. How Rhea-AI works. Not financial advice.
